SBI-087

DRUG4 trials

Sponsors

Pfizer

Conditions

Active Rheumatoid ArthritisArthritis, RheumatoidLupus Erythematosus, SystemicRheumatoid Arthritis

Phase 1

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

CompletedNCT00641225

PfizerRheumatoid Arthritis

Start: 2008-03-31End: 2011-03-31Updated: 2023-09-13

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

CompletedNCT00714116

PfizerLupus Erythematosus, Systemic

Start: 2009-03-31End: 2012-09-30Updated: 2018-12-07

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

CompletedNCT00815906

PfizerArthritis, Rheumatoid

Start: 2008-12-31End: 2012-05-31Updated: 2024-08-14

Phase 2

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

CompletedNCT01008852

PfizerActive Rheumatoid Arthritis

Start: 2009-12-31End: 2013-07-31Updated: 2013-12-03

Related Papers

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.

2016-04-214 citations